Expert: Potential Surufatinib FDA Approval for Neuroendocrine Tumors Is "Really Exciting"

Surufatinib targets both the VEGF receptor and the CSF1R receptor, which is a unique mechanism of action.

In an interview with Pharmacy Times about her presentation at the North American Neuroendocrine Tumor Society (NANETS) 2021 neuroendocrine tumor (NET) Medical Symposium, Mei Ka Fong, PharmD, BCOP, said the potential FDA approval of surufatinib could be very important for patients.

Fong said surufatinib targets both the VEGF receptor and the CSF1R receptor, which is a unique mechanism of action.By targeting both receptors, surufatinib targets both the angiogenesis and the tumor tumor's immune evasion, which could make a significant difference in the treatment of NETs.